Full-Time

Associate Director

Nonclinical Program Development

Posted on 9/9/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$181k - $214k/yr

+ Annual bonus + Long-term incentive award + Equity

Boston, MA, USA

Hybrid

Minimum two days on-site per week, currently Tuesday and Wednesday.

Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • PhD, DVM, PharmD, MS, or equivalent advanced degree in toxicology, pharmacology, immunology, cellular/molecular biology, biomedical sciences, or a related discipline.
  • At least 7 years of relevant biotechnology, pharmaceutical, CRO, academic translational research, or consulting experience, including meaningful experience supporting nonclinical development programs.
  • Experience contributing to or leading nonclinical toxicology strategies for development-stage therapeutic programs, including IND-enabling study design and interpretation.
  • Working knowledge of GLP toxicology studies, safety pharmacology, PK/PD, toxicokinetics, biodistribution, and regulatory expectations for nonclinical packages.
  • Experience in immunology, inflammation, autoimmune disease, immune-mediated diseases, T-cell biology, cell therapy, biologics, gene therapy, or other novel therapeutic modalities.
  • Experience supporting first-in-human readiness, clinical biomarker strategy, or translational safety monitoring.
  • Familiarity with regulatory interactions such as INTERACT, Pre-IND, IND, NDA/BLA, or equivalent health authority submissions.
  • Experience working with academic collaborators, external scientific consultants, and specialized translational or biomarker assay vendors.
  • Experience reviewing or contributing to nonclinical study reports, IND/CTD sections, briefing packages, or other regulatory documents.
  • Experience in a small biotech, startup, or virtual operating model requiring hands-on execution, vendor management, and strategic problem-solving.
  • Demonstrated ability to manage external CROs and vendors and coordinate study execution across multiple stakeholders.
  • Strong project and program management capability, including timeline planning, cross-functional coordination, risk tracking, deliverable management, and issue escalation.
  • Ability to communicate scientific and operational issues clearly to cross-functional teams and senior stakeholders.
Responsibilities
  • Support and help drive nonclinical toxicology strategy for assigned pipeline assets by contributing to integrated safety plans covering toxicology, toxicokinetics, safety pharmacology, immunotoxicology, reproductive and developmental toxicology, carcinogenicity considerations, and other modality-specific assessments required for clinical development and regulatory filings.
  • Provide program-management and operational leadership for nonclinical development activities by building and maintaining study plans, timelines, risk logs, decision trackers, vendor deliverables, and cross-functional action plans aligned with program milestones, governance expectations, and regulatory submission timelines.
  • Support organization of central repositories by guiding the systematic arrangement of nonclinical reports and data sets consistently across programs.
  • Oversee CRO and external-partner execution, including CRO and vendor identification, selection, contracting input, study start-up, protocol review, study monitoring, issue escalation, quality oversight, GLP compliance expectations, data delivery, and final report review for nonclinical toxicology and translational studies.
  • Contribute to IND-enabling and regulatory documentation by authoring, reviewing, and coordinating toxicology and nonclinical study reports, nonclinical regulatory sections, briefing-book materials, responses to health-authority questions, and study-level documentation required for INDs and other global submissions.
  • Identify nonclinical safety risks and mitigation strategies by assessing knowledge gaps, interpreting emerging nonclinical data, integrating cross-functional input, and proposing pragmatic mitigation plans for timely, science-based decisions.
  • Partner with Translational Medicine and Clinical Development to bridge nonclinical findings to clinical monitoring by aligning nonclinical safety observations, translational biomarkers, sample-collection plans, laboratory-readiness activities, and clinical-monitoring approaches for first-in-human and clinical studies.
  • Collaborate across matrixed teams, including Toxicology, Translational Medicine, Clinical Pharmacology, Regulatory, CMC, Quality, Clinical Development, Program Management, medical writing, academic collaborators, consultants, and CRO partners, to ensure integrated execution.
  • Perform other duties and responsibilities as assigned.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...